Trials / Completed
CompletedNCT03995888
Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer
A Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation Dosimetry of rhPSMA-7.3 (18F) Injection in Healthy Volunteers, and to Assess Safety and Investigate the Imaging Characteristics in Subjects With Prostate Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Blue Earth Diagnostics · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
A Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation Dosimetry of rhPSMA-7.3 (18F) Injection in Healthy Volunteers, and to Assess Safety and Investigate the Imaging Characteristics in Subjects With Prostate Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhPSMA-7.3 (18F) Injection | Radioligand for PET CT scanning |
Timeline
- Start date
- 2019-06-11
- Primary completion
- 2020-04-16
- Completion
- 2020-04-16
- First posted
- 2019-06-24
- Last updated
- 2026-02-12
- Results posted
- 2026-02-12
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT03995888. Inclusion in this directory is not an endorsement.